Day One Biopharmaceuticals Inc’s recently made public that its CHIEF EXECUTIVE OFFICER Bender Jeremy unloaded Company’s shares for reported $0.16 million on May 03 ’24. In the deal valued at $17.85 per share,9,154 shares were sold. As a result of this transaction, Bender Jeremy now holds 642,602 shares worth roughly $10.67 million.
Then, York Charles N II sold 8,078 shares, generating $144,214 in total proceeds. Upon selling the shares at $17.85, the COO, CFO AND SECRETARY now owns 217,293 shares.
Before that, York Charles N II sold 200 shares. Day One Biopharmaceuticals Inc shares valued at $3,579 were divested by the COO, CFO AND SECRETARY at a price of $17.90 per share. As a result of the transaction, York Charles N II now holds 225,371 shares, worth roughly $3.74 million.
Needham reiterated its Day One Biopharmaceuticals Inc [DAWN] rating to a Buy in a research note published on April 24, 2024; the price target was $33. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in late April from “a Buy” to “an Underperform”. CapitalOne began covering DAWN with “an Overweight” recommendation on February 08, 2023. Oppenheimer started covering the stock on February 03, 2023. It rated DAWN as “a Perform”.
Price Performance Review of DAWN
On Monday, Day One Biopharmaceuticals Inc [NASDAQ:DAWN] saw its stock fall -3.32% to $16.60. Over the last five days, the stock has gained 0.73%. Day One Biopharmaceuticals Inc shares have risen nearly 13.70% since the year began. Nevertheless, the stocks have risen 22.24% over the past one year. While a 52-week high of $18.07 was reached on 05/01/24, a 52-week low of $9.67 was recorded on 04/25/24. SMA at 50 days reached $15.45, while 200 days put it at $13.72. A total of 1.13 million shares were traded, compared to the trading of 0.72 million shares in the previous session.
Levels Of Support And Resistance For DAWN Stock
The 24-hour chart illustrates a support level at 16.35, which if violated will result in even more drops to 16.11. On the upside, there is a resistance level at 16.97. A further resistance level may holdings at 17.35. The Relative Strength Index (RSI) on the 14-day chart is 54.84, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.15, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 29.11%. Stochastics %K at 81.06% indicates the stock is a selling.
The most recent change occurred on December 15, 2022 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
